Close
Data Completeness
Individual Datasets
Datasets
Pediatric Completeness
Pediatric Individual Datasets
Data Dictionary
Data Completeness
| 2021 - Completeness | |
|---|---|
| N datasets | 8* |
| N observations | 17507 |
| Age | 100.0% |
| Sex | 100.0% |
| HIV status | 99.5% |
| Past treatment | 71.9% |
| AFB positive at baseline | 89.3% |
| Culture converted at month 6 | 64% |
| Culture converted at month 2 | 20.7% |
| Outcome | 100.0% |
| Relapse | 2.1% |
| Lzd resistant at baseline | 2.5% |
| Mfx resistant at baseline | 5.4% |
| Lfx resistant at baseline | 4.6% |
| Ofx resistant at baseline | 8% |
| Cfx resistant at baseline | 0% |
| Bdq resistant at baseline | 1.4% |
*two datasets from South Africa are counted as one Original Data Curator: Prof Greg Fox, The University of Sydney, Australia
Individual Datasets
| 2021 - individual datasets | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Author | Overall | Belarus | Georgia | Moldova | Somalia | South Africa | France | Nix Comparator | Einstein |
| WHO Region |
| European | European | European | Eastern Mediterranean | African | Multi-region | African | African |
| Type of Study |
| Unpublished | Unpublished | Unpublished | Unpublished | Unpublished | Unpublished | Unpublished | Unpublished |
| N observations | 17507 | 99 | 151 | 132 | 25 | 16619 | 218 | 102 | 161 |
| Age ≥ 18 years | 95.3% | 98.0% | 97.4% | 100.0% | 68.0% | 95.2% | 99.5% | 100.0% | 99.4% |
| Sex, male | 58.8% | 59.6% | 78.1% | 77.3% | 64.0% | 58.3% | 67.9% | 63.7% | 59.0% |
| HIV positive | 66.7% | 9.1% | 4.0% | 14.4% | - | 68.9% | 11.9% | 51.0% | 67.1% |
| Recieved previous TB treatment | 43.9% | 59.6% | 73.5% | 82.6% | 44.0% | 43.8% | - | - | 74.5% |
| Previous treatment: FLD | 1.2% | 41.4% | 41.1% | 73.5% | 48.0% | - | - | - | - |
| Previous treatment: SLD | 2.3% | 47.5% | 65.6% | 73.5% | - | - | - | 87.3% | 41.0% |
| AFB positive | 38.2% | 49.5% | 68.2% | 58.3% | - | 37.2% | 72.0% | 49.0% | 48.4% |
| Culture converted before month 2 | 20.7% | 96.0% | 35.8% | 31.8% | 72.0% | 20.6% | - | - | - |
| Culture converted before month 6 | 64.0% | 93.9% | 78.1% | 65.9% | 72.0% | 65.5% | - | - | - |
| Outcome: cured | 48.6% | 72.7% | 69.5% | 65.2% | 72.0% | 48.0% | 80.3% | - | 54.0% |
| Outcome: treatment complete | 15.6% | 11.1% | 7.3% | 2.3% | 28.0% | 15.6% | 7.3% | 64.7% | 13.7% |
| Outcome: lost to follow-up | 16.0% | 7.1% | 11.9% | 9.1% | - | 16.3% | 8.7% | 11.8% | 18.6% |
| Outcome: treatment failed | 2.0% | 4.0% | 6.6% | 19.7% | - | 1.8% | 1.4% | 4.9% | 3.1% |
| Outcome: death | 17.7% | 5.1% | 4.6% | 3.8% | - | 18.3% | 2.3% | 18.6% | 10.6% |
| Relapse | .1% | 1% | 4% | 1.5% | - | - | - | - | - |
| Lzd resistant at baseline | 0.1% | - | - | 0.8% | - | 0.1% | 1.4% | - | - |
| Mfx resistant at baseline | 2.1% | 35.4% | 15.9% | 53.8% | - | 0.8% | 22.9% | - | 36.6% |
| Lfx resistant at baseline | 1.4% | 73.7% | - | 78.8% | - | 0.4% | - | - | 1.2% |
| Ofx resistant at baseline | 3.1% | 22.2% | 88.7% | 34.8% | - | 0.8% | 29.4% | 68.6% | 39.1% |
| Cfx resistant at baseline | - | - | - | 1.5% | - | - | - | - | - |
| Bdq resistant at baseline | 0.2% | - | 0.7% | 1.5% | - | 0.1% | 2.3% | - | - |
*percentages relative to total number of observations per dataset;
Original Data Curator: Prof Greg Fox, The University of Sydney, Australia
Datasets
Please note there is a traffic light system for the datasets.
Green: Available
Yellow: In process
Red: Unavailable
White: In negotiation
Pediatric Completeness
| SUN - completeness | |
|---|---|
| N datasets | 8 |
| N observations | 939 |
| age | 99.9% |
| sex | 99.9% |
| disease site | 99.1% |
| AFB positive at baseline | 43% |
| Outcome | 99.9% |
| Lzd resistant at baseline | 0 |
| Mfx resistant at baseline | 0.3% |
| Lfx resistant at baseline | 0 |
| Ofx resistant at baseline | 24.3% |
| Cfx resistant at baseline | 8.7% |
| Bdq resistant at baseline | 0 |
Original Data Curator: Stellenbosch University, South Africa
Pediatric Individual Datasets
| SUN - individual datasets | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Author | Overall | Becerra2016 | Hicks2014 | Lopez_varela_2020 | MDRPK2_2022 | Migliori_2020_Cfz_Brazil_v2 | Ozere2020 | Seddon2012 | Seddon2014 |
WHO Region |
|
|
|
|
|
|
|
|
|
Type of Study |
|
|
|
|
|
|
|
|
|
N observations | 939 | 232 | 82 | 136 | 77 | 140 | 53 | 88 | 131 |
Age, median | 6.9% | 11.0% | 8.6% | 3.3% | 4.0% | 18.0% | 4.4% | 3.8% | 2.8% |
Sex, male | 45.9% | 45.7% | 43.9% | 50.0% | 48.1% | 47.1% | 39.6% | 39.8% | 47.3% |
disease site | 82.9% | 82.9% | 82.9% | 82.9% | 82.9% | 82.9% | 82.9% | 82.9% | 82.9% |
AFB positive | 27.1% | 50.0% | - | 13.2% | - | 85.7% | - | - | - |
Outcome: cured | 37.1% | 31.9% | 61.0% | 17.6% | 40.3% | 40.0% | 17.0% | 84.1% | 22.9% |
Outcome: treatment complete | 33.4% | 38.4% | 19.5% | 2.9% | 5.2% | 32.1% | 81.1% | 15.9% | 75.6% |
Outcome: lost to follow-up | 6.2% | 12.5% | 6.1% | 5.1% | - | 10.7% | 1.9% | - | 0.8% |
Outcome: treatment failed | 1.8% | 4.3% | 4.9% | - | - | 2.1% | - | - | - |
Outcome: death | 17.4% | 9.1% | - | 74.3% | 53.2% | - | - | - | - |
Lzd resistant at baseline | - | - | - | - | - | - | - | - | - |
Mfx resistant at baseline | 0.1% | - | - | - | - | 0.7% | - | - | - |
Lfx resistant at baseline | - | - | - | - | - | - | - | - | - |
Ofx resistant at baseline | 14.8% | - | - | 5.9% | 10.4% | 2.1% | 9.4% | 90.9% | 26.7% |
Cfx resistant at baseline | 0.3% | 1.3% | - | - | - | - | - | - | - |
Bdq resistant at baseline | - | - | - | - | - | - | - | - | - |
*percentages relative to total number of observations per dataset;
Original Data Curator: Stellenbosch University, South Africa
The 2021 Data Dictionary can be accessed here
